id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0847-0014,FDA,FDA-2012-D-0847,"Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, etc.",Notice,Guidance,2013-08-27T04:00:00Z,2013,8,2013-08-27T04:00:00Z,,2024-11-07T22:58:30Z,2013-20822,1,0,09000064813c68e3
FDA-2012-D-0847-0001,FDA,FDA-2012-D-0847,"Draft Guidance for IRBs, Clinical Investigators, and Sponsors; Availability: IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed",Notice,Notice of Availability,2012-11-20T05:00:00Z,2012,11,2012-11-20T05:00:00Z,2013-01-23T04:59:59Z,2013-01-25T03:01:05Z,2012-28149,0,0,090000648116eb29
FDA-2012-D-0847-0002,FDA,FDA-2012-D-0847,"Draft Guidance for IRBs, Clinical Investigators, and Sponsors; IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed",Other,Guidance,2012-11-20T05:00:00Z,2012,11,2012-11-20T05:00:00Z,,2019-10-21T14:42:58Z,,0,0,090000648116ec2a